Home > Niels Reinmuth, ESMO 2019 – Phase III MYSTIC trial in NSCLC
Lung Cancer

Niels Reinmuth, ESMO 2019 – Phase III MYSTIC trial in NSCLC

Published Online: October 7th 2019

We are joined by Niels Reinmuth (Asklepios Kliniken Munich-Gauting) at ESMO 2019 to discuss his presentation on PD-L1 expression in primary tumours versus metastatic samples in the phase III MYSTIC study in first-line metastatic NSCLC.

Questions
1.   Could you tell us a little about the MYSTIC study and its major findings? (00:07)
2.   What was the relationship between programmed death-ligand 1 (PD-L1) expression and the efficacy of durvalumab? (00:50)
3.   How did the expression of PD-L1 differ between primary tumour and metastatic samples? (01:30)
4.    What are the implications of these findings for clinical practice? (01:51)

Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.

Speaker disclosure: Neils Reinmuth disclosed a relevant relationship with AstraZeneca.

touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.

Share this Video
Related Videos In Lung Cancer
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar